[ad_1]
This press release was originally distributed by SBWire
Albany, NY – (SBWIRE) – 05/02/2019 – Several medications are being treated for the treatment of constipation caused by opioids. Once approved, these drugs will face little competition in this largely untapped market. There have not been many stable choices in the pharmaceutical industry over the past few years for the treatment of opioid-induced constipation, but the ongoing approval rate of highly targeted drugs is expected to strongly boost the rate of growth of opioids. this market. This includes PAMORA medications that help treat the symptoms without interfering with the opioid action on the patient.
The number of patients suffering from opioid-induced constipation is steadily increasing worldwide. According to the American Academy of Pain Medicine, nearly 100 million US patients in 2013 were suffering from OCI. They added that this number is expected to increase along with the number of people consuming opioid medications. Conscious of the increasing availability of a wide variety of opioids on the market, people tend to use them in the longer term to treat chronic pain. This growing number of OIC patients – particularly in North America – is expected to further stimulate the demand for treatment of opioid-induced constipation.
However, conventional laxatives face competition from providers of opioid-induced constipation. Most health care organizations still consider standard laxatives as the first line of treatment for the OIC. In addition, long-term adverse effects of constipation treatments caused by opioids have not been fully documented.
In total, the global market for the treatment of constipation caused by opioids is expected to be valued at US $ 731.2 million by the end of 2016. Due to an impressive CAGR of 31.2 % between 2015 and 2023, this product is expected to reach 4.8 billion US dollars by 2023.
Request for posting a sample report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6862
North America has historically absorbed a significant portion of the world's consumption of drugs for the treatment of opioid-induced constipation. By the end of 2023, North America alone is expected to generate $ 4.05 billion in global revenues from opioid-induced constipation treatments. This region is also leading in terms of the growth rate of demand, because of the high percentage of the population that consumes opioid drugs and suffers from OIC. This comes from a large number of patients with chronic diseases who use opioids.
In addition, penetration of opioid-induced constipation treatments is very low in other regions compared to North America. This could explain the wide disparity in consumption rates between regions. At the present time, North America dominates in terms of opioid consumption. According to ASIPP, the United States alone consumes nearly 80% of the world's opioid supply.
Until the end of 2016, chlorinated channel activators should be the most popular clbad of drugs for treating opioid-induced constipation. This trend will continue over the next few years, but it is anticipated that mu-opioid receptor antagonists will ultimately play the leading role among drug clbades. One of the main reasons for the popularity of chlorinated channel activators is the high level of sales of Amitiza since its approval in 2013 and its specific use in the treatment of opioid-induced constipation.
Over time, the growing number of approved mu-opioid receptor antagonists and their increased efficacy over other clbades of drugs should propel it to the forefront in terms of revenue generation by 2023. This clbad of drugs will benefit also the number of prescriptions being processed for opioid-induced constipation due to developments reducing their side effects.
Request to view the report brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=6862
The leading providers of treatment for opioid-induced constipation include AstraZeneca, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant, Bayer, BC Fleet Company, Inc., Boehringer Ingelheim, Daewoong Co. Ltd. and Cosmo Pharmaceuticals.
For more information on this press release, go to the following address: http://www.sbwire.com/press-releases/opioid-induced-constipation-treatment-market-is- expected-to-reach-us48-bn-by-2023-1139578 .htm
[ad_2]
Source link
